drugset / Trial / NCT00827112

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

NCT00827112

Phase 2 Completed 129 enrolled ViiV Healthcare Pfizer · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a pilot study to examine if the novel treatment regimen maraviroc plus boosted atazanavir can be expected to be safe and efficacious in treatment naive HIV infected patients. Based on the results from this study, a confirmatory phase 3 study may be conducted.

Timeline

Start
2009-03
Primary completion
2010-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 150 mg
Subject Tenofovir Small molecule 300 mg
Subject emtricitabine Other / unclassified 200 mg
Background Atazanavir Other / unclassified 300 mg
Background Darunavir Small molecule 800 mg
Background Lopinavir Other / unclassified 400 mg
Background Ritonavir Other / unclassified 100 mg